What is the recommended management for a 6.6 cm exophytic renal mass?

Management of a 6.6 cm Exophytic Renal Mass

For a 6.6 cm exophytic renal mass, radical nephrectomy is the recommended treatment, preferably via a minimally invasive approach (laparoscopic or robotic), as this tumor size (T2) exceeds the threshold for partial nephrectomy in most cases 1, 2.

Surgical Approach

This 6.6 cm mass falls into the T2 category (>7 cm would be T2a, but masses between 4-7 cm are T1b). However, given its size approaching 7 cm, the treatment paradigm aligns with T2 management:

• Minimally invasive radical nephrectomy is the preferred option for tumors of this size 2
• Partial nephrectomy becomes technically challenging and is generally not recommended for masses >7 cm unless there are imperative indications (solitary kidney, bilateral tumors, or compromised renal function) 2
• The exophytic nature of the mass is favorable but does not change the size-based recommendation at 6.6 cm

Key Decision Points

When Partial Nephrectomy Should Be Considered:

Despite the size, partial nephrectomy may still be appropriate if:

• Imperative indications exist: solitary kidney, bilateral tumors, or pre-existing chronic kidney disease 2
• The patient has compromised renal function where nephron preservation is critical
• The exophytic location makes complete resection with adequate margins technically feasible

Pre-operative Workup:

• Renal mass biopsy is NOT routinely required before surgery for masses of this size, as the probability of malignancy is high and surgical intervention is indicated regardless 2
• Complete staging with cross-sectional imaging (CT or MRI) to assess for lymphadenopathy, venous involvement, and metastatic disease 1, 2

Non-Surgical Options Are NOT Appropriate

At 6.6 cm, the following are explicitly contraindicated:

• Ablative therapies (RFA, cryoablation): Guidelines recommend against RFA for tumors >3 cm and cryoablation for tumors >4 cm 1
• Stereotactic body radiotherapy (SBRT): Only considered for T1a or select T1b tumors in medically unfit patients 1, 2
• Active surveillance: Only appropriate for small renal masses (≤4 cm) in elderly/comorbid patients, not for a 6.6 cm mass 1, 2

Common Pitfalls to Avoid

1. Do not perform routine adrenalectomy or lymph node dissection unless there is radiographic or intraoperative evidence of involvement 2
2. Do not delay surgery for neoadjuvant therapy outside of clinical trials—this remains investigational 1
3. Assess renal function carefully: If the contralateral kidney is normal and the mass is truly exophytic with favorable anatomy, discuss partial nephrectomy with an experienced surgeon, but radical nephrectomy remains standard for this size

Post-Operative Considerations

• Risk stratification: Use the KEYNOTE-564 classification to determine if adjuvant pembrolizumab is indicated (for intermediate-high or high-risk disease) 2
• Pathology review: Confirm histologic subtype and grade to guide surveillance and potential adjuvant therapy decisions 2